June 2019 - Volume 3 - Issue - Contributor Index

Author:
K, R. L
Author:
Kaastrup, K.
Author:
Kaaz, K.
Author:
Kabanova, A.
Author:
Kabat, B. F.
Author:
Kabelitz, D.
Author:
Kabir, S.

CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) INHIBITOR, REDUCES PRO-INFLAMMATORY CYTOKINES, BONE MARROW FIBROSIS AND THE NUMBER OF TRANSFUSIONS IN MYELOFIBROSIS PATIENTS: S831

Hoffman, R.; Mascarenhas, J.; Kremyanskaya, M.; More

HemaSphere. 3:369, June 2019.

Author:
Kacem, K.
Author:
Kacem, S.

EVALUATION OF SERINE BIOSYNTHESIS PATHWAY AS A POTENTIAL THERAPEUTIC TARGET IN BURKITT LYMPHOMA: PF524

Noyszewska-Kania, M.; Bialopiotrowicz, E.; Cybulska, M.; More

HemaSphere. 3:214-215, June 2019.

Author:
Kaczynski, H.

THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY: PF558

De Oca, Montes R.; Bhattacharya, S.; Vitali, N.; More

HemaSphere. 3:231, June 2019.

Author:
Kadel, S.-K.
Author:
Kader, A.
Author:
Kadia, T.

RNA BASED IMMUNE SIGNATURES MAY PREDICT RESPONSES TO PD-1 INHIBITION AND AZACITIDINE TREATMENT IN ACUTE MYELOID LEUKEMIA (AML): A SUBSET ANALYSIS OF A PHASE 2 STUDY: PF205

Abbas, H.; Alfayez, M.; Wang, F.; More

HemaSphere. 3:54-55, June 2019.

A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL-2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1-MUTATED (MIDH1) MYELOID MALIGNANCIES: PF291

Dinardo, C.; Takahashi, K.; Kadia, T.; More

HemaSphere. 3:97, June 2019.

PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML): PF673

Bose, P.; Verstovsek, S.; Naqvi, K.; More

HemaSphere. 3:289-290, June 2019.

EXPLORATORY ANALYSIS OF OUTCOMES WITH SEQUENTIAL FLT3-INHIBITOR (FLT3I) BASED THERAPIES IN RELAPSED FLT3-MUTATED AML PATIENTS (PTS): PS1064

Alfayez, M.; Kantarjian, H.; Ravandi, F.; More

HemaSphere. 3:481-482, June 2019.

CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA: S1614

Angenendt, L.; Röllig, C.; Montesinos, P.; More

HemaSphere. 3:744-745, June 2019.

IMPACT OF CD33 AND ABCB1 SINGLE NUCLEOTIDE POLYMORPHISMS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH DECITABINE PLUS GEMTUZUMAB OZOGAMICIN: PB1722

Short, N.; Richard-Carpentier, G.; Kanagal-Shamanna, R.; More

HemaSphere. 3:791-792, June 2019.

Author:
Kadia, T. M.

SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.: S1615

Daver, N.; Alfayez, M.; Garcia-Manero, G.; More

HemaSphere. 3:745, June 2019.

Author:
Kadish, K.

PROGNOSTIC TESTING AND TREATMENT APPROACHES BASED ON REAL-WORLD CLINICAL EXPERIENCE FROM AN INTERIM ANALYSIS OF THE INFORMCLL REGISTRY OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: PF383

Mato, A. R.; Barrientos, J. C.; Brander, D.; More

HemaSphere. 3:143-144, June 2019.

Author:
Kadkhoda, H.
Author:
Kadnikova, T.

PROGNOSTICATION OF HODGKIN'S LYMPHOMA BY IPET AND IPS: UPDATE DATA OF 8 HEMATOLOGICAL UKRAINIAN CENTERS.: PB1996

Novosad, O.; Skrypets, T.; Pastushenko, I.; More

HemaSphere. 3:903-904, June 2019.

Author:
Kafantari, A.
Author:
Kafantari, K.
Author:
Kaguelidou, F.
Author:
Kahl, B.

POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) AND LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): INTERIM ANALYSIS OF A PHASE IB/II TRIAL: S102

Abrisqueta, P.; Kahl, B.; Banerjee, L.; More

HemaSphere. 3:2-3, June 2019.

Author:
Kaiser, K.

PATIENT PREFERENCES FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS OF A PATIENT SURVEY OF RAVULIZUMAB (ALXN1210) AND ECULIZUMAB: PF734

Peipert, J. D.; Kulasekararaj, A.; Gaya, A.; More

HemaSphere. 3:321, June 2019.

Author:
Kaiser, L. M.
Author:
Kaiser, M.

RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA: S823

Mateos, M.-V.; Nahi, H.; Legiec, W.; More

HemaSphere. 3:364, June 2019.

EFFICACY OF QUADRUPLET KCRD (CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE AND DEXAMETHASONE) INDUCTION FOR NEWLY DIAGNOSED MYELOMA PATIENTS: ANALYSIS OF THE MYELOMA XI STUDY BY MOLECULAR RISK: S873

Pawlyn, C.; Kaiser, M.; Davies, F.; More

HemaSphere. 3:391, June 2019.

Author:
Kaivers, J.

IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA - A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP: S840

Pleyer, L.; Leisch, M.; Kouraklis, A.; More

HemaSphere. 3:374-375, June 2019.

Author:
Kaizer, H.
Author:
Kakadiya, P. M.
Author:
Kakinoki, Y.

EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY: PF184

Shigematsu, A.; Ota, S.; Kobayashi, R.; More

HemaSphere. 3:44, June 2019.

TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4: PF407

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3:155-156, June 2019.

CONSOLIDATION THERAPY USING 90Y-IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012): PS1263

Tsujimura, H.; Miura, K.; Kanno, M.; More

HemaSphere. 3:578, June 2019.

Author:
Kakkar, N.
Author:
Kako, S.

EVALUATION OF THE IMMUNITY TO MEASLES, MUMPS AND RUBELLA IN ADULT PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: PS1277

Kawamura, K.; Nakasone, H.; Wada, H.; More

HemaSphere. 3:584-585, June 2019.

SAFETY AND EFFICACY OF LIVE ATTENUATED VARICELLA VACCINE FOR PREVENTING VARICELLA ZOSTER VIRUS DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE SINGLE-CENTER STUDY: S1639

Kawamura, K.; Nakasone, H.; Akahoshi, Y.; More

HemaSphere. 3:758, June 2019.

Author:
Kakuta, Y.
Author:
Kalabus, J.

EVALUATION OF AMG 420, AN ANTI-BCMA BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST-IN-HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY: S825

Topp, M.; Duell, J.; Zugmaier, G.; More

HemaSphere. 3:365, June 2019.

Author:
Kalakonda, N.

UPDATE OF THE SINGLE-ARM PHASE II L-MIND STUDY OF MOR208 PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: HIGH OVERALL RESPONSE RATES IN PATIENT SUBGROUPS WITH POOR PROGNOSIS: PF296

Duell, J.; Maddocks, K.; Barca, González E.; More

HemaSphere. 3:100, June 2019.

EFFICACY WAS IMPROVED WITH LENALIDOMIDE/RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH FOLLICULAR LYMPHOMA IRRESPECTIVE OF POD24 STATUS IN THE PHASE III AUGMENT STUDY: PF483

Leonard, J. P.; Trneny, M.; Izutsu, K.; More

HemaSphere. 3:193-194, June 2019.

PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT): PS1252

Gribben, J.; Trneny, M.; Izutsu, K.; More

HemaSphere. 3:571-572, June 2019.

POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: PS1262

Thieblemont, C.; Leonard, J. P.; Trneny, M.; More

HemaSphere. 3:577-578, June 2019.

Author:
Kalff, A.

THE AUSTRALASIAN LEUKAEMIA AND LYMPHOMA (ALLG) GROUP MM17 TRIAL: RESPONSE ADAPTIVE SALVAGE WITH CARFILZOMIB-THALIDOMIDE-DEXAMETHASONE FOR MULTIPLE MYELOMA PATIENTS FAILING FRONT-LINE BORTEZOMIB: PF604

Spencer, A.; Quach, H.; Horvath, N.; More

HemaSphere. 3:255-256, June 2019.

PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN THE ELRDELRY AND YOUNGER ADULTS: REAL-WORLD COMPARATIVE RETROSPECTIVE STUDY FROM THE ITP REGISTRY OF THE HELLENIC SOCIETY OF HEMATOLOGY: PF693

Pontikoglou, C.; Kaliafentaki, V.; Stavroulaki, E.; More

HemaSphere. 3:301, June 2019.

Author:
Kalina, T.

MONOCYTIC SWITCH AND DISCREPANCY BETWEEN FLOW CYTOMETRIC AND MOLECULAR MINIMAL RESIDUAL DISEASE ARE FREQUENT IN DUX4 REARRANGED AND PAX5-P80R MUTATED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: PF176

Novakova, M.; Vakrmanova, B.; Slamova, L.; More

HemaSphere. 3:40-41, June 2019.

Author:
Kállay, K.

DNA HYPERMETHYLATION EMERGES AS THE STRONGEST PREDICTOR FOR POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML): PF677

Niemeyer, C. M.; Flotho, C.; Lipka, D. B.; More

HemaSphere. 3:292, June 2019.

Author:
Kallel, C.
Author:
Kallel, F.
Author:
Kalpadakis, C.

COMPARISON OF RITUXIMAB DOSE-ADJUSTED EPOCH (R-DA-EPOCH) WITH RITUXIMAB-CHOP (R-CHOP) CHEMOTHERAPY IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): PF297

Vassilakopoulos, T.; Mellios, Z.; Verigou, E.; More

HemaSphere. 3:100-101, June 2019.

PET-SCAN FOR RESPONSE ASSESSEMENT AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): CLINICAL AND PROGNOSTIC SIGNIFICANCE: PS1089

Vassilakopoulos, T.; Chatzidimitriou, C.; Mellios, Z.; More

HemaSphere. 3:494, June 2019.

CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): CLINICAL SIGNIFICANCE OF ABSOLUTE CLONAL B CELL COUNTS: PS1258

Kalpadakis, C.; Pangalis, G.; Konstantinou, I.; More

HemaSphere. 3:575, June 2019.

EVALUATION OF THE QUANTITATIVE CHARACTERISTICS OF MYELOID DERIVED SUPPRESSOR CELLS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND ASSOCIATED HYPOGAMMAGLOBULINEMIA: PB1881

Zavisanou, K.; Bizymi, N.; Ioneskou, K.; More

HemaSphere. 3:857, June 2019.

Author:
Kalter, D.
Author:
Kalwak, K.
Author:
Kalyva, S.
Author:
Kamachi, K.
Author:
Kamal, T.
Author:
Kamalakar, R.
Author:
Kamara, I.
Author:
Kamata, K.
Author:
Kambhampati, S.
Author:
Kameda, K.

EVALUATION OF THE IMMUNITY TO MEASLES, MUMPS AND RUBELLA IN ADULT PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: PS1277

Kawamura, K.; Nakasone, H.; Wada, H.; More

HemaSphere. 3:584-585, June 2019.

SAFETY AND EFFICACY OF LIVE ATTENUATED VARICELLA VACCINE FOR PREVENTING VARICELLA ZOSTER VIRUS DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE SINGLE-CENTER STUDY: S1639

Kawamura, K.; Nakasone, H.; Akahoshi, Y.; More

HemaSphere. 3:758, June 2019.

Author:
Kamel-Reid, S.

DOUBLING TIME AFTER FIRST ATTEMPT OF IMATINIB DISCONTINUATION IS HELPFUL TO IDENTIFY THE BEST CANDIDATE FOR THE SECOND ATTEMPT FOR TREATMENT-FREE REMISSION WITH DASATINIB: CANADIAN TRAD TRIAL: PF410

Kim, D.; Busque, L.; Forrest, D.; More

HemaSphere. 3:157-158, June 2019.

ASSESSMENT OF MOLECULAR MRD KINETICS BY ERROR-CORRECTED NEXT-GENERATION SEQUENCING PROVIDES INDEPENDENT PROGNOSTIC INFORMATION IN ADULT AML PATIENTS: PS1027

Murphy, T.; Zou, J.; Wang, T. T.; More

HemaSphere. 3:463, June 2019.

Author:
Kamelskikh, D.

PD-1 PATHWAY IS A KEY IMMUNOSUPPRESSIVE MECHANISM IN PATIENTS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH TCR AB-DEPLETION: PF755

Popova, N.; Drokov, M.; Davydova, Y.; More

HemaSphere. 3:331-332, June 2019.

Author:
Kamermans, A.
Author:
Kamesaki, T.
Author:
Kamoun, H.
Author:
Kampfenkel, T.

PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS: S145

Moreau, P.; Attal, M.; Hulin, C.; More

HemaSphere. 3:24-25, June 2019.

STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY: PF598

Hulin, C.; Moreau, P.; Attal, M.; More

HemaSphere. 3:252, June 2019.

EFFICACY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA BASED ON MINIMAL RESIDUAL DISEASE STATUS: ANALYSIS OF CASSIOPEIA: S874

Avet-Loiseau, H.; Moreau, P.; van der Velden, V. H.J.; More

HemaSphere. 3:391-392, June 2019.

IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT-ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY: PS1377

Roussel, M.; Moreau, P.; Attal, M.; More

HemaSphere. 3:630, June 2019.

Author:
Kamran, I.
Show: